231	0	t-Butyl	256	1	t-Butyl	281	2	t-Butyl
232	0	Propyl	257	1	Propyl	282	2	Propyl
233	0	Benzyl	258	1	Benzyl	283	2	Benzyl
234	0	Allyl	259	1	Allyl	284	2	Allyl
235	0	CF_3	260	1	CF_3	285	2	CF_3
236	0		261	1		286	2	
237	0		262	1		287	2	
238	0		263	1		288	2	
239	0		264	1		289	2	
240	0		265	1		290	2	
241	0		266	1		291	2	
242	0		267	1		292	2	
243	0		268	1		293	2	
244	0		269	1		294	2	
245	0		270	1		295	2	
246	0		271	1		296	2	
247	0		272	1		297	2	
248	0		273	1		298	2	
249	0		274	1		299	2	
250	0		275	1		300	2	

14. Use of a therapeutically effective amount of a compound of formula (I) according to any one of claims 1-13 in the manufacture of a medicament for the prevention or treatment of an FXR-mediated disease or condition in a mammal wherein the medicament is to be administered to the mammal suffering from the FXR-mediated disease or condition.

15. The use according to claim 14, wherein the FXR-mediated disease or condition is selected from the group consisting of chronic liver disease, gastrointestinal disease, renal disease, cardiovascular disease, and metabolic disease.

16. The use according to claim 15, wherein the chronic liver disease is selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), drug induced cholestasis, intrahepatic cholestasis of pregnancy, parenteral nutrition associated cholestasis (PNAC), bacterial overgrowth or sepsis associated cholestasis, autoimmune hepatitis, chronic viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver transplant associated graft versus host disease, living donor transplant liver regeneration, congenital hepatic fibrosis, choledocholithiasis, granulomatous liver disease, intra- or extrahepatic malignancy, Sjogren's syndrome, Sarcoidosis, Wilson's disease, Gaucher's disease, hemochromatosis, and alpha 1-antitrypsin deficiency.

17. The use according to claim 15, wherein the renal disease is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, and polycystic kidney disease.

18. The use according to claim 15, wherein the cardiovascular disease is selected from the group consisting of atherosclerosis, arteriosclerosis, dyslipidemia, hypercholesterolemia, and hypertriglyceridemia.

19. The use according to claim 15, wherein the metabolic disease is selected from the group consisting of insulin resistance, Type I and Type II diabetes, and obesity.

20. Use of a therapeutically effective amount of a compound of formula (I) according to any one of claims 1-13 in the manufacture of a medicament for the prevention or treatment of an TGR5-mediated disease or condition in a mammal wherein the medicament is administered to the mammal suffering from the TGR5-mediated disease or condition.